TGA statement on the discontinuation of Ordine
Palliative care professionals are alerted to the Ordine Discontinuation Statement.
Ordine (morphine) is an essential medicine used to manage severe pain and difficult or laboured breathing in many care settings, including cancer treatment and end-of-life care.
The Therapeutic Goods Administration (TGA) has been notified of Mundipharma’s intention to discontinue supply of all Ordine oral liquid medicines in Australia. All Ordine oral liquid supplies are expected to be depleted between November 2023 and May 2024.
Prescribers should identify patients taking Ordine oral liquid and discuss with their patients the implications of this discontinuation on their treatment plan.
The TGA acknowledges the discontinuation of Ordine oral liquid medicines may cause distress for some patients and also recognises that many health professionals are very concerned about the future management options for pain and breathing issues for some patient groups.
To help manage the discontinuation of Ordine oral liquid for patients and health professionals, the TGA has granted approval for the supply of several overseas registered morphine oral liquid products under section 19A of the Therapeutic Goods Act 1989.
More information can be found in the TGA statement about the discontinuation of Ordine (morphine) oral liquid
